VaxInnate - Crunchbase Company Profile & Funding
网页VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology.
VaxInnate Corporation Enhances R&D Program and Strengthens …
网页2015年5月15日 · VaxInnate is a privately held biotechnology company in Cranbury, NJ that is pioneering a breakthrough technology platform for use in developing novel and proprietary vaccines. Influenza vaccines...
Recent Progress in Recombinant Influenza Vaccine Development …
网页2022年5月19日 · Vaccine development requires understanding of viral pathogenesis and host immune response. In humans, infection starts through binding of viral glycoproteins to sialic acid residues on epithelial cell surfaces of the upper and lower respiratory tracts (56) followed by influenza replication, as shown in Figure 2 .
Flu vaccine makers upgrade technology—and pray for time
网页VaxInnate, which closed a $30 million financing round in May, is developing both seasonal and pandemic vaccines, based on recombinant proteins that can be rapidly produced in high volumes in ...
VaxInnate Company Profile 2024: Valuation, Funding & Investors
网页Developer of vaccines designed to cure flu, malaria, dengue, papillomavirus and respiratory syncytial virus. The company's vaccines are made by genetically fusing vaccine antigens to the bacterial protein flagellin that improves vaccine immunogenicity and efficacy, enabling patients to begin treatment more quickly, resulting in a higher ...
Recent Advances in the Development of Toll-like Receptor Agonist …
网页2022年2月16日 · Vaccines are powerful tools for controlling microbial infections and preventing epidemic diseases. Efficient inactive, subunit, or viral-like particle vaccines usually rely on a safe and potent adjuvant to boost the immune response to the antigen.
VaxInnate commences quadrivalent seasonal influenza vaccine candidate ...
网页2015年6月3日 · Biotechnology firm VaxInnate has commenced a Phase II study to assess the safety and immunogenicity of its quadrivalent seasonal influenza vaccine candidate, VAX2012Q. Fluzone Quadrivalent, which is a commercially available vaccine, is the active comparator in the study.
Efficacious recombinant influenza vaccines produced by high yield ...
网页2008年5月21日 · It is known that physical linkage of TLR ligands and vaccine antigens significantly enhances the immunopotency of the linked antigens. We have used this approach to generate novel influenza vaccines that fuse the globular head domain of the protective hemagglutinin (HA) antigen with the potent TLR5 ligand, flagellin.
BioCentury - VAX2012Q: Phase Ib/II started
网页2015年1月5日 · VaxInnate began a double-blind, placebo-controlled Phase Ib/II trial to evaluate single doses of 12, 20, 28 or 36 µg VAX2012Q in up to 200 healthy voluntee...
BioCentury - VAX2012Q: Phase I started
网页2014年3月24日 · VaxInnate began an open-label, dose-escalation, U.S. Phase I trial to evaluate 4-30 µg of intramuscular VAX2012Q in up to 320 healthy volunteers ages 18-40. The trial is funded by VaxInnate's 2011 con...
跳至内容